當前一代的季節(jié)性流感疫苗的藥效，因需要利用過時的和費時的技術來生產新疫苗,、以應對迅速變化的病毒而受到限制,。這項研究提出了流感疫苗接種的一個新方法：利用融合到天然病毒附著蛋白“血凝素”上的自組裝的、基于“鐵蛋白”的納米顆粒,。“血凝素-納米顆粒”疫苗被發(fā)現(xiàn)誘導中和抗體,，對各種病毒亞型的免疫力高于某種獲準上市的流感疫苗。例如,，由一種1999年的“血凝素-納米顆粒”疫苗誘發(fā)的抗體中和了從1934年到2007年的H1N1病毒,，保護雪貂不被2007年的H1N1病毒感染。（生物谷Bioon.com）
生物谷推薦英文摘要：
Nature doi:10.1038/nature12202
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Masaru Kanekiyo, Chih-Jen Wei, Hadi M. Yassine, Patrick M. McTamney, Jeffrey C. Boyington, James R. R. Whittle, Srinivas S. Rao, Wing-Pui Kong, Lingshu Wang & Gary J. Nabel
Influenza viruses pose a significant threat to the public and are a burden on global health systems1, 2. Each year, influenza vaccines must be rapidly produced to match circulating viruses, a process constrained by dated technology and vulnerable to unexpected strains emerging from humans and animal reservoirs. Here we use knowledge of protein structure to design self-assembling nanoparticles that elicit broader and more potent immunity than traditional influenza vaccines. The viral haemagglutinin was genetically fused to ferritin, a protein that naturally forms nanoparticles composed of 24 identical polypeptides3. Haemagglutinin was inserted at the interface of adjacent subunits so that it spontaneously assembled and generated eight trimeric viral spikes on its surface. Immunization with this influenza nanoparticle vaccine elicited haemagglutination inhibition antibody titres more than tenfold higher than those from the licensed inactivated vaccine. Furthermore, it elicited neutralizing antibodies to two highly conserved vulnerable haemagglutinin structures that are targets of universal vaccines: the stem4, 5 and the receptor binding site on the head6, 7. Antibodies elicited by a 1999 haemagglutinin–nanoparticle vaccine neutralized H1N1 viruses from 1934 to 2007 and protected ferrets from an unmatched 2007 H1N1 virus challenge. This structure-based, self-assembling synthetic nanoparticle vaccine improves the potency and breadth of influenza virus immunity, and it provides a foundation for building broader vaccine protection against emerging influenza viruses and other pathogens.
